FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns a method of treating a neoplastic disease involving administering to a subject in need of such treatment a pharmaceutical composition containing a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition further contains a pharmaceutically acceptable carrier, wherein said compound is astarabine, wherein the therapeutically effective amount of astarabine is a daily dose of 0.5 g/m2 up to 10 g/m2 body surface area of the subject. Group of inventions also relates to a method of treating a neoplastic disease comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of astarabine, wherein the undesirable events from the above compound are reduced compared to the undesired effects of unconjugated cytarabine, such that the compound can be administered in a dose at least twice the standard dose of cytarabine, and wherein the subject will not experience dose-limiting toxicity, wherein said pharmaceutical composition further contains a pharmaceutically acceptable carrier.
EFFECT: group of inventions provides treating a neoplastic disease.
31 cl, 2 dwg, 2 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
CONJUGATE SALTS FOR CANCER TREATMENT | 2016 |
|
RU2747528C2 |
METHOD OF TREATMENT BY APPLICATION OF COMBINED THERAPY | 2010 |
|
RU2543348C2 |
PHORBOL ESTER COMPOSITIONS AND METHODS OF USING THEM FOR TREATING OR REDUCING DURATION OF CYTOPENIA | 2015 |
|
RU2730998C2 |
RARA AGONISTS FOR THE TREATMENT OF AML AND MDS | 2017 |
|
RU2799789C2 |
TREATMENT METHOD FOR ACUTE MYELOID LEUKEMIA | 2020 |
|
RU2812782C2 |
DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | 2014 |
|
RU2680246C1 |
DRUG COMBINATIONS | 2014 |
|
RU2708246C2 |
METHODS OF APPLYING (+)-1,4-DIHYDRO-7-[(3S, 4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(THIAZOLYL)-1,8-NAPHTHIRIDINE-3-CARBOXYLIC ACID FOR CANCER TREATMENT | 2006 |
|
RU2592231C2 |
NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
Authors
Dates
2019-12-11—Published
2016-01-25—Filed